Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab

[Guest guest]

[Treatment of chronic lymphocytic leukemia with regimen of fludarabine,

cyclophosphamide and rituximab.]

WJ Gu, W Xu, SX Qian, YJ Wu, M Hong, LJ Chen, HX Wu, H Lu, HX Qiu, and JY Li

Zhongguo Shi Yan Xue Ye Xue Za Zhi, August 1, 2008; 16(4): 938-42.

Department 0f Hematology, The First Hospital, Nanjing Medical University,

Jiangsu Province People Hospital, Nanjing 210029, Jiangsu Province, China.

In order to evaluate the efficiency of rituximab combined with fludarabine,

cyclophosphamide and rituximab (FCR) regimen for chronic lymphocytic leukemia

(CLL). Five patients with CLL were treated with FCR regimen for 2 - 6 courses.

FCR regimen included fludarabine 25 mg/m(2) via intraveneous drip at day 2 - 4,

cyclophosphamide 250 mg/m(2) via intraveneous drip at day 2 - 4 and rituximab

375 mg/m(2) via intraveneous drip at day 1. Courses were repeated every 4 weeks.

Minimal residual disease (MRD) was determined by multiparametic flow cytometry.

The results showed that three patiens achieved complete remission, 2 patients

achieved partial remission. MRD was negative in two patiens. In conclusion, FCR

is an effective therapeutic regimen for treating CLL patients and is worth to be

used in clinic.

PMID: 18718095